Britain and America have hammered out a key bilateral deal that will ensure no tariffs on UK medicine exports being sold in the American market.
The Terms of the Pact
As part of the deal, the UK has pledged to raise funding on pharmaceuticals through the NHS. This move guarantees that duties on these vital exports will remain at zero for a period of the next three years.
This development is in response to recent statements to hike tariffs on branded pharmaceutical products, with potential rates mentioned reaching 100%.
"This arrangement with the United Kingdom reinforces the global environment for innovative medicines and brings long-overdue equity to American-British pharmaceutical trade," a release noted.
Trade Significance
Medicines constitute one of the the United Kingdom's biggest export categories to the America, which is clearly the biggest buyer for large companies like GSK and AstraZeneca.
Trade data show that in the 12 months to the end of the third quarter, the UK shipped drugs valued at £11.1bn to the US. This figure accounted for nearly one-fifth of total UK exports in that timeframe.
"This agreement safeguards employment, stimulates funding and sets the stage for the UK to establish itself as a worldwide center for life sciences," a minister commented.
Key NHS Changes
The deal includes several specific changes from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it judges new medicines to be too expensive by 25%.
- Increased NHS Spending: There is a goal to increase total NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Payback Limit: The percentage drug companies must refund to the NHS to stay within budget will be limited at 15%. In the past, repayments topped 20%.
Recent Tensions
This agreement follows a protracted dispute between the sector and the UK government over medicine costs and regulatory access.
These tensions were heightened by claims that US customers were charged several times more for the equivalent treatments than patients in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been delayed or cancelled, while substantial expansions have been directed toward projects in the United States.
One official publicly accepted that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had decreased as a proportion of its resources over the previous ten-year period.
